1. Home
  2. III vs ACIU Comparison

III vs ACIU Comparison

Compare III & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Information Services Group Inc.

III

Information Services Group Inc.

HOLD

Current Price

$3.99

Market Cap

193.7M

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.14

Market Cap

221.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
III
ACIU
Founded
2006
2003
Country
United States
Switzerland
Employees
1500
122
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
193.7M
221.9M
IPO Year
2006
2015

Fundamental Metrics

Financial Performance
Metric
III
ACIU
Price
$3.99
$2.14
Analyst Decision
Buy
Strong Buy
Analyst Count
1
2
Target Price
$5.50
$10.00
AVG Volume (30 Days)
257.8K
256.1K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
4.46%
N/A
EPS Growth
216.67
N/A
EPS
0.05
N/A
Revenue
$192,745,000.00
N/A
Revenue This Year
$3.85
$706.75
Revenue Next Year
$4.34
$321.13
P/E Ratio
$81.50
N/A
Revenue Growth
4.51
N/A
52 Week Low
$3.74
$2.03
52 Week High
$6.45
$4.00

Technical Indicators

Market Signals
Indicator
III
ACIU
Relative Strength Index (RSI) 44.73 36.96
Support Level $3.88 $2.15
Resistance Level $4.33 $2.66
Average True Range (ATR) 0.15 0.15
MACD -0.00 -0.02
Stochastic Oscillator 22.06 11.11

Price Performance

Historical Comparison
III
ACIU

About III Information Services Group Inc.

Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: